Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients

BACKGROUND: Approximately 5–20% of chronic myeloid leukemia (CML) patients demonstrate primary resistance or intolerance to imatinib. None of the existing predictive scores gives a good prognosis of TKI efficacy. Gene polymorphisms, expression and microRNAs are known to be involved in the pathogenes...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Med Genomics
Egile Nagusiak: Lavrov, Alexander V., Chelysheva, Ekaterina Yu., Adilgereeva, Elmira P., Shukhov, Oleg A., Smirnikhina, Svetlana A., Kochergin-Nikitsky, Konstantin S., Yakushina, Valentina D., Tsaur, Grigory A., Mordanov, Sergey V., Turkina, Anna G., Kutsev, Sergey I.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2019
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6416830/
https://ncbi.nlm.nih.gov/pubmed/30871622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12920-019-0481-z
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak